Literature DB >> 19590235

Association of secondary hyperparathyroidism with CKD progression, health care costs and survival in diabetic predialysis CKD patients.

Glen T Schumock1, Dennis L Andress, Steven E Marx, Raimund Sterz, Amie T Joyce, Kamyar Kalantar-Zadeh.   

Abstract

BACKGROUND/AIMS: The objective of this study was to examine health care costs and utilization and the risks of dialysis or mortality among diabetic predialysis chronic kidney disease (CKD) patients with and without secondary hyperparathyroidism (SHPT).
METHODS: This retrospective, matched cohort study examined insurance claims from 703 adult diabetic predialysis CKD patients with and without SHPT during a 72-month follow-up period. Annualized estimates of health care service utilization, costs and disease progression to dialysis or death following index CKD diagnosis were compared.
RESULTS: Preindex (baseline) characteristics were similar between the cohorts. Postindex numbers of prescription utilization, outpatient service utilization and hospitalizations were all higher (p < 0.0001) in diabetic CKD patients with SHPT compared to those without SPHT in both unadjusted and adjusted analyses even after multivariate adjustment for known confounders. The rate of progression to dialysis or death was higher for diabetic CKD patients with SHPT compared to those without SPHT. Those with SHPT were at higher risk of requiring dialysis treatment [hazard ratio (HR) = 6.7; 95% confidence interval (CI) = 4.3-10.6] and death (HR = 2.3; 95% CI = 1.1-4.9) compared to those without SHPT.
CONCLUSION: In diabetic predialysis CKD patients, the presence of SHPT is associated with significantly greater health care resource utilization and costs, and a faster rate of disease progression.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19590235     DOI: 10.1159/000228076

Source DB:  PubMed          Journal:  Nephron Clin Pract        ISSN: 1660-2110


  23 in total

Review 1.  Renal and extrarenal actions of Klotho.

Authors:  Ming Chang Hu; Makoto Kuro-o; Orson W Moe
Journal:  Semin Nephrol       Date:  2013-03       Impact factor: 5.299

2.  Reforming medicare's dialysis payment policies: implications for patients with secondary hyperparathyroidism.

Authors:  Charu Gupta; Glenn M Chertow; Mark T Linthicum; Karen Van Nuys; Vasily Belozeroff; Darryl Quarles; Darius N Lakdawalla
Journal:  Health Serv Res       Date:  2014-07-07       Impact factor: 3.402

3.  Elevated serum parathyroid hormone is a cardiovascular risk factor in moderate chronic kidney disease.

Authors:  Anton Lishmanov; Smrita Dorairajan; Youngju Pak; Kunal Chaudhary; Anand Chockalingam
Journal:  Int Urol Nephrol       Date:  2011-02-15       Impact factor: 2.370

4.  Chronic kidney disease progression and outcome according to serum phosphorus in mild-to-moderate kidney dysfunction.

Authors:  Antonio Bellasi; Marcora Mandreoli; Leopoldo Baldrati; Matteo Corradini; Pierpaolo Di Nicolò; Giulio Malmusi; Antonio Santoro
Journal:  Clin J Am Soc Nephrol       Date:  2011-03-10       Impact factor: 8.237

5.  The association of parathyroid hormone with ESRD and pre-ESRD mortality in the Kidney Early Evaluation Program.

Authors:  Georges Saab; Andrew S Bomback; Samy I McFarlane; Suying Li; Shu-Cheng Chen; Peter A McCullough; Adam Whaley-Connell
Journal:  J Clin Endocrinol Metab       Date:  2012-10-12       Impact factor: 5.958

Review 6.  Emerging risk factors and markers of chronic kidney disease progression.

Authors:  Florian Kronenberg
Journal:  Nat Rev Nephrol       Date:  2009-12       Impact factor: 28.314

7.  High burden and unmet patient needs in chronic kidney disease.

Authors:  Leeann Braun; Vipan Sood; Susan Hogue; Bonnie Lieberman; Catherine Copley-Merriman
Journal:  Int J Nephrol Renovasc Dis       Date:  2012-12-13

Review 8.  Which vitamin D in CKD-MBD? The time of burning questions.

Authors:  Andrea Galassi; Antonio Bellasi; Sara Auricchio; Sergio Papagni; Mario Cozzolino
Journal:  Biomed Res Int       Date:  2013-08-07       Impact factor: 3.411

9.  Health state utilities associated with major clinical events in the context of secondary hyperparathyroidism and chronic kidney disease requiring dialysis.

Authors:  Evan W Davies; Louis S Matza; Gavin Worth; David H Feeny; Jacqueline Kostelec; Steven Soroka; David Mendelssohn; Philip McFarlane; Vasily Belozeroff
Journal:  Health Qual Life Outcomes       Date:  2015-06-30       Impact factor: 3.186

10.  Impact of mineral and bone disorder on healthcare resource use and associated costs in the European Fresenius medical care dialysis population: a retrospective cohort study.

Authors:  Silvia Chiroli; Caroline Mattin; Vasily Belozeroff; Louise Perrault; Dominic Mitchell; Ioanna Gioni
Journal:  BMC Nephrol       Date:  2012-10-29       Impact factor: 2.388

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.